

# EZZ

Our mission is to improve quality of  
life and human health.

**FY23 (unaudited) Results Presentation**

Glenn Cross, Non-Executive Director and Chair

Tony Guarna, Chief Financial Officer



# DISCLAIMER

This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (**Company**). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below.

This document is not a prospectus, product disclosure statement or other offer document under Australian law or under any other law and has not been filed, registered or approved by regulatory authorities in any jurisdiction. This document does not constitute an offer, invitation, solicitation or recommendation to acquire any shares in the Company. The information contained in this document is not intended to be relied upon as advice or a recommendation to investors and does not take into account the investment objectives, financial situation, taxation situation or needs of any particular investor. An investor must not act on the basis of any matter contained in this document but must make its own assessment of the Company and conduct its own investigations and analysis. Investors should assess their own individual financial circumstances and consider talking to a financial adviser, professional adviser or consultant before making any investment decision. The information contained in this document is supplied in summary form and does not contain all information necessary to make an investment decision.

Neither the Company nor any of its directors, officers, employees, contractors, agents or advisers (**Limited Party**) makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this document. No Limited Party represents or warrants that this document is complete or that it contains all information about the Company that a prospective investor may require in evaluating a possible investment in the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault, negligence or omission on the part of any person, for any loss or damage arising from the use of, or reliance on, information contained in this document or otherwise arising in connection with it.

Certain statements in this document constitute forward looking statements and comments about future events, including with respect to the financial condition, results of operations and business of the Company and certain plans and objectives of the management of the Company. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance. Given these uncertainties, you are cautioned to not place undue reliance on any forward looking statement. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. No Limited Party or any other person makes any representation as to the accuracy or likelihood of the fulfilment of any forward-looking statements, or gives any assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statements in this document will occur.

# EZZ

# Contents

EZZ



FY23 Highlights



FY23 Financial Performance



Strategy



Outlook for FY24



Q&A

# FY23 Highlights

## Strong Financial Performance

Strong revenue growth of 147.3% from \$15m last year to \$37.1m in FY23.

Operating cash inflow of \$4m, up from \$1.9m in FY22

Substantial gross margin expansion to 76.8% this year from 50.0% last year

## New Distribution Channels and Geographical Markets

Strong growth on the Douyin platform (launched Q4 FY22)

New presence on Amazon Australia and eBay Australia

Landmark distribution partnership with HIC

New geographical markets such as Vietnam

## New Product Development

Eighteen new products under its own brand and distributed several new products under the EAORON brand

Consumer insights from e-commerce presence provide deep knowledge of consumer preferences

# FY23 Operational Overview

## Research and Development

**18** new products  
under the EZZ brand

## Channel Diversification

**5** new channels  
added to e-commerce strategies

## Market Exposure

**4** International Expos  
expansion strategy

## Revenue from the Best-Selling Product

**19.7%**  
up from 17% in FY22

## Revenue from the Best Performing Channel

**51.4%**  
up from 15.5% in FY22

## Revenue from the Largest Customer

**12%**  
up from 11.5% in FY22

# Our Products

## EZZ

We formulate, produce, market and distribute health supplements under the brand of EZZ. Our deep understanding of our target consumers allows us to develop products that address their health and wellness needs.

### Top 3 Products by Revenue in FY23



NMN 150,000 mcg



L-Lysine Growth Capsule



Bone Growth Chews

## EAORON

We are an exclusive wholesale distributor of skin care products under the EAORON brand in Australia and New Zealand to pharmacies, supermarkets and specialist retailers.

### Top 3 Products by Revenue in FY23



Hyaluronic Acid Collagen Hydrating Face Mask



Hyaluronic Acid Collagen Essence



Instant Brightening Face Mask

# FY23 Financial Overview

Revenue

**\$37.1M**

Up by 147.3% from FY22

EBITDA

**\$5.1M**

Up by 167.7% from FY22

Cash on Hand

**\$13.8M**

Up by 32.2% from FY22  
(No external debt)

Gross Margin

**76.8%**

Up from 50% in FY22

NPAT

**\$3.6M**

Up by 176.6% from FY22


Interim Dividend

**\$0.0098**

1H FY23

# Revenue

Record revenue growth as a result of successful market-driven R&D, dynamic channel prioritisation, and targeted B2C marketing






# Margins

Attractive gross margin are well maintained and improving


## Gross Margin




# Profitability

Solid operating profit and strong growth momentum fuelled by successful investments in marketing

EBITDA (Exclude Other Income)




Operating Expense Breakdown



# Working Capital


Well maintained working capital position to accelerate continuous growth

## Working Capital Movements




# Cash Flow

Cash flow from operating activities more than doubled from a year ago



# Financial Position






<sup>1</sup> Excluding lease liabilities

# Strategy




## Life Science

Product development pipeline to increasingly feature healthcare solutions based on scientific research

-  Genomics
-  Enzyme
-  Stem cell




## Technology

Online store and data backed analytical capability to enable data driven decision making

-  Streamlined process with real-time data
-  Personalised customer experience
-  Pricing and promotion structures flexibility





## People

Ongoing investment in people and talent to support growth while carefully managing cost base

-  Cultural compatibility
-  Engagement models diversification
-  Talent motivation

## Consumers

Connection to consumers through omni-channel strategies in targeted sectors and regions

-  Wholesalers
-  Retailers
-  eCommerce
-  Social commerce and selling

Research & development

Supply chain

Manufacturing

Sales & marketing

Data analytics

# Outlook

- Landmark partnership with HIC with sales commencing Q1 FY24
- Gradual resumption of inbound leisure travel from China to Australia and New Zealand
- Pipeline of new products
- Actively exploring new geographical markets
- Strong cash position to explore M&A opportunities as they arise

EZZ



# EZZ

## Q&A

Glenn Cross, Non-Executive Director and Chair  
Tony Guarna, Chief Financial Officer





# EZZ LIFE SCIENCE HOLDINGS LIMITED

[ASX: EZZ]

# EZZ

FINANCIAL REVIEW

**FAST**   
**GLOBAL**

EZZ Life Science Holdings Limited  
ABN 83 608 363 604

104 Derby Street,  
Silverwater NSW 2128

T: 02 9160 2305  
E: [ir@ezzlife.com.au](mailto:ir@ezzlife.com.au)

[www.ezzlife.com.au](http://www.ezzlife.com.au)



[EZZLifescience](#)



[linkedin.com/company/  
ezz-life-science-holdings](https://linkedin.com/company/ezz-life-science-holdings)



[EZZAustralia](#)



[EZZ\\_Australia](#)